KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Cash from Operations (2016 - 2025)

Historic Cash from Operations for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $197.2 million.

  • West Pharmaceutical Services' Cash from Operations rose 949.47% to $197.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $693.8 million, marking a year-over-year decrease of 122.44%. This contributed to the annual value of $653.4 million for FY2024, which is 1585.32% down from last year.
  • According to the latest figures from Q3 2025, West Pharmaceutical Services' Cash from Operations is $197.2 million, which was up 949.47% from $177.1 million recorded in Q2 2025.
  • In the past 5 years, West Pharmaceutical Services' Cash from Operations ranged from a high of $239.1 million in Q4 2023 and a low of $88.7 million during Q1 2021
  • For the 5-year period, West Pharmaceutical Services' Cash from Operations averaged around $170.6 million, with its median value being $169.2 million (2023).
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 7046.22% in 2022, then plummeted by 2172.97% in 2024.
  • Over the past 5 years, West Pharmaceutical Services' Cash from Operations (Quarter) stood at $160.8 million in 2021, then skyrocketed by 43.53% to $230.8 million in 2022, then increased by 3.6% to $239.1 million in 2023, then fell by 20.49% to $190.1 million in 2024, then increased by 3.73% to $197.2 million in 2025.
  • Its last three reported values are $197.2 million in Q3 2025, $177.1 million for Q2 2025, and $129.4 million during Q1 2025.